Neuroblastoma New Diagnosis
Neuroblastoma New Diagnosis
ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
- Ages: 365 days to 30 Years
BRIEF SUMMARY: This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor c ...More
IRP-101-301: Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
- Ages: No Limit
This is a prospective, Phase 3, multi-center, open-label study designed to assess the use of 18F-mFBG PET imaging in subjects with known or presumed neuroblastoma. Eligible participants will have either histopathologically established diagnosis of neuroblastoma or a presumed diagnosis based on signs ...More
Contact Us
To learn more about available neuroblastoma clinical trials, contact us at cancer@cchmc.org or 513-636-2799.
Related Topic
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2023 Cincinnati Children's Hospital Medical Center. All rights reserved.
